Unlocking Precision Cancer therapy: New Biosensor Reveals Vulnerability in MTAP-deleted Tumors
For decades, protein arginine methyltransferase 5 (PRMT5) has been a prime target in cancer drug finding. now, a groundbreaking collaboration between researchers at stony Brook University, the University of Oxford, Boston University, and Promega Corporation has unveiled a critical link between tumor metabolism and drug efficacy, potentially paving the way for highly targeted cancer treatments. The research, published recently, details a novel approach to identifying and characterizing drugs that selectively target cancer cells with a specific genetic mutation, while sparing healthy tissue – a long-sought goal in oncology.
The MTAP Mutation: A Unique Cancer Vulnerability
Approximately 10-15% of all cancers harbor a mutation in the MTAP gene. This seemingly small genetic alteration creates a notable vulnerability. In normal cells,PRMT5 functions with a molecule called SAM. However, when MTAP is mutated, PRMT5 instead interacts with a molecule called MTA. This shift in binding partners fundamentally alters PRMT5S behaviour, creating a unique targetable state exclusive to these tumor cells.
“Selectivity is one of the most critical challenges in cancer therapy,” explains Dr. Peter J. Tonge, Professor of Chemistry at Stony Brook University and Visiting Professor at the University of Rochester. “Most treatments damage healthy cells, leading to dose-limiting toxicities and reduced therapeutic effectiveness. Our work identifies a new class of tumor-specific drugs that exploit this metabolic difference, limiting activity to tumor tissue.”
NanoBRET Technology: illuminating Drug-Target Engagement
The key to this breakthrough lies in the growth of a sophisticated method to quantify the interaction between PRMT5 and potential inhibitors specifically when PRMT5 is bound to MTA – the form present in MTAP-mutated tumor cells. Researchers leveraged NanoBRET (Bioluminescent Resonance Energy Transfer), a well-established biosensor technology, to achieve this.
NanoBRET allows scientists to observe drug-target engagement in live cells, providing a dynamic and physiologically relevant picture of how inhibitors behave. This is a significant advancement over conventional methods that frequently enough rely on static, in vitro experiments.
CBH-002: A Metabolic Biosensor for Precision Targeting
The University of Oxford team, led by Dr. Elizabeth Mira Rothweiler, designed and developed CBH-002, a cell-permeable NanoBRET probe. This probe binds to a genetically encoded PRMT5-NanoLuc biosensor, effectively reporting when a drug is engaging its target within the cell.
“CBH-002 could measure various PRMT5 inhibitor types in live cells, prompting us to test its sensitivity to the cofactor SAM,” explains Dr. Rothweiler. “When we discovered the probe’s ability to sense metabolite levels, it established its utility as a metabolic biosensor. Through collaboration with Promega, we demonstrated how MTA influences drug selectivity, revealing why certain inhibitors are so effective in MTAP-deleted cancers.”
Uncompetitive Inhibition: A Novel Mechanism Revealed
The research team discovered that certain PRMT5 inhibitors act through an “uncompetitive” or “cooperative” mechanism. This means they only bind effectively to the PRMT5-MTA complex, and their binding is influenced by the presence of MTA itself. This is a crucial finding, as it explains why these inhibitors are so potent against MTAP-deleted cancers, while exhibiting minimal activity against normal cells.
“To our knowledge, this is the first time anyone has characterized this type of uncompetitive inhibitor mechanism directly in live cells,” adds Ani Michaud, Senior Research Scientist at Promega and co-first author.
Implications for Future Cancer Treatment
This research provides unprecedented insight into the metabolic vulnerabilities of MTAP-deleted cancers. By understanding how different inhibitors interact with PRMT5 under specific metabolic conditions, researchers can design drugs that are far more effective and less toxic.
“This provides unprecedented insight into why certain inhibitors are much more effective in cancers lacking MTAP and paves the way for highly targeted cancer treatment in the future,” says Dr. Kilian Huber, Associate Professor at the Center for Medicines Discovery. “it’s like turning on the lights inside the cell so we can finally see which key actually fits the lock.”
Looking Ahead
The development of CBH-002 and the insights gained from this research represent a significant step forward in precision oncology.the ability to accurately measure drug-target engagement in live cells, coupled with a deeper understanding of tumor metabolism, will accelerate the development of more effective and targeted cancer therapies. This work,supported by the National Institutes of Health (NIH),
Keep reading